Stay updated on Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial page.

Latest updates to the Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial page
- CheckyesterdayChange DetectedRevision tag on the page was updated from v3.6.4 to v3.6.5, reflecting a new build of the ClinicalTrials.gov interface. This change is a minor UI/backend update and does not modify study data or visible content on the page.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRevision label updated to v3.6.4 on the page, representing a version update in the page template without altering study details. No content changes to the study information are introduced.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedThe page revision tag was updated from v3.6.2 to v3.6.3, indicating a minor documentation/version update.SummaryDifference0.0%

- Check44 days agoChange DetectedRevision: v3.6.2 was added and v3.6.0 was removed. This indicates a page update or maintenance rather than any new or altered study details.SummaryDifference0.0%

- Check59 days agoChange DetectedNew help/navigation sections were added: How to Read a Study Record, Common Questions, and How to Join a Study. A recruitment status note indicates enrollment is closed ('No longer looking for participants'), and a site revision (Revision: v3.6.0) was added.SummaryDifference0.3%

- Check66 days agoChange DetectedRevision: v3.5.5 has been added to indicate the latest update to the page content. The previous revision, v3.5.4, has been removed.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab±Anetumab in Mesothelin+ Pleural Mesothelioma Clinical Trial page.